Urogen Pharma $URGN Position Raised by Truist Financial Corp

Truist Financial Corp boosted its position in Urogen Pharma (NASDAQ:URGN) by 134.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,286 shares of the company’s stock after purchasing an additional 41,436 shares during the period. Truist Financial Corp’s holdings in Urogen Pharma were worth $1,442,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of URGN. Osaic Holdings Inc. raised its stake in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. Strs Ohio acquired a new position in Urogen Pharma during the third quarter worth about $76,000. CWM LLC raised its position in Urogen Pharma by 18.0% in the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after acquiring an additional 650 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after acquiring an additional 5,571 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Urogen Pharma by 9.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after acquiring an additional 797 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $21.35 on Monday. The firm has a 50 day simple moving average of $21.96 and a 200 day simple moving average of $20.68. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The company has a market cap of $999.39 million, a PE ratio of -6.17 and a beta of 1.33.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. On average, equities analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on URGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Finally, D. Boral Capital restated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Friday, January 23rd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.